These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 10366112

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP.
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [Abstract] [Full Text] [Related]

  • 23. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 24. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
    Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK.
    Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
    [Abstract] [Full Text] [Related]

  • 31. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital.
    Joven BE, Almodovar R, Carmona L, Carreira PE.
    Semin Arthritis Rheum; 2010 Feb; 39(4):285-93. PubMed ID: 19782387
    [Abstract] [Full Text] [Related]

  • 32. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.
    Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR.
    J Rheumatol; 1998 Jan; 25(1):84-8. PubMed ID: 9458208
    [Abstract] [Full Text] [Related]

  • 33. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
    Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I.
    Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
    [Abstract] [Full Text] [Related]

  • 34. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.
    Poormoghim H, Lucas M, Fertig N, Medsger TA.
    Arthritis Rheum; 2000 Feb; 43(2):444-51. PubMed ID: 10693887
    [Abstract] [Full Text] [Related]

  • 35. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 36. Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.
    Hakoda M, Taniguchi A, Kamatani N, Akahoshi T, Kashiwazaki S.
    J Rheumatol; 1994 Sep; 21(9):1637-41. PubMed ID: 7799341
    [Abstract] [Full Text] [Related]

  • 37. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 38. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
    Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D, Investigators of the D-Penicillamine, Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials.
    Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
    [Abstract] [Full Text] [Related]

  • 39. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ, MBBQ Study Group.
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [Abstract] [Full Text] [Related]

  • 40. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
    Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P.
    J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.